• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Puma Biotechnology (NQ: PBYI )

    3.620 +0.010 (+0.28%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Jul 30, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 373,913
    Open 3.630
    Bid (Size) 3.610 (5)
    Ask (Size) 3.980 (39)
    Prev. Close 3.610
    Today's Range 3.620 - 3.790
    52wk Range 2.130 - 7.730
    Shares Outstanding 47,509,765
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Where Puma Biotechnology Stands With Analysts
    Via Benzinga
    Puma Biotechnology to Host Conference Call to Discuss Second Quarter 2024 Financial Results
    From Puma Biotechnology, Inc.
    Via Business Wire

    Performance

    YTD
    -20.00%
    -20.00%
    1 Month
    +10.37%
    +10.37%
    3 Month
    -28.60%
    -28.60%
    6 Month
    -24.03%
    -24.03%
    1 Year
    N/A
    N/A

    More News

    Read More
    Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
    From Puma Biotechnology, Inc.
    Via Business Wire
    Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
    From Puma Biotechnology, Inc.
    Via Business Wire
    Beyond The Numbers: 4 Analysts Discuss Puma Biotechnology Stock
    Via Benzinga
    Earnings Scheduled For February 29, 2024
    Via Benzinga
    Puma Biotechnology Announces Presentation of Findings from a Phase I/Ib Study of Alisertib in Advanced EGFR-Mutated Lung Cancer
    From Puma Biotechnology, Inc.
    Via Business Wire
    Puma Biotechnology Announces Presentation of Findings from a Phase II Study of Alisertib in Endocrine-Resistant Metastatic Breast Cancer (TBCRC 041)
    From Puma Biotechnology, Inc.
    Via Business Wire
    Puma Biotechnology to Join Russell 3000 Index
    From Puma Biotechnology, Inc.
    Via Business Wire
    Puma Biotechnology Announces Publication of Alisertib Abstract Titles for the 2024 ASCO Annual Meeting
    From Puma Biotechnology, Inc.
    Via Business Wire
    Pfizer Wins $107.5M Verdict Against AstraZeneca Over Cancer Drug Patent Dispute
    Via Benzinga
    Topics Intellectual Property
    Exposures Intellectual Property
    PBYI Stock Earnings: Puma Biotechnology Beats EPS, Beats Revenue for Q1 2024
    Via InvestorPlace
    Puma Biotechnology Reports First Quarter Financial Results
    From Puma Biotechnology, Inc.
    Via Business Wire
    7 Stocks Under $15 Predicted to Boom in the Next 2 Years
    Via InvestorPlace
    Puma Biotechnology to Host Conference Call to Discuss First Quarter 2024 Financial Results
    From Puma Biotechnology, Inc.
    Via Business Wire
    Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
    From Puma Biotechnology, Inc.
    Via Business Wire
    Puma Biotechnology Announces FDA Allowance to Proceed Under IND for Alisertib in HER2-Negative, Hormone Receptor-Positive Metastatic Breast Cancer
    From Puma Biotechnology, Inc.
    Via Business Wire
    10 Health Care Stocks With Whale Alerts In Today's Session
    Via Benzinga
    Puma Biotechnology Reports Fourth Quarter and Full Year 2023 Financial Results
    From Puma Biotechnology, Inc.
    Via Business Wire
    Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
    From Puma Biotechnology, Inc.
    Via Business Wire
    Puma Biotechnology to Participate in a Panel Discussion at TD Cowen’s 44th Annual Health Care Conference
    From Puma Biotechnology, Inc.
    Via Business Wire
    Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year 2023 Financial Results
    From Puma Biotechnology, Inc.
    Via Business Wire
    12 Health Care Stocks Moving In Wednesday's Intraday Session
    Via Benzinga
    Puma Biotechnology Announces Initiation of ALISCA-Lung1 Phase II Trial of Alisertib in Small Cell Lung Cancer
    From Puma Biotechnology, Inc.
    Via Business Wire
    3 small-cap biotechs with potential breakthroughs in 2024
    Via MarketBeat
    Topics Bankruptcy
    Exposures Financial Legal
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.